Neuron23

San Francisco, United States

Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.

Jun 2026

Grant

Top Investors

Kleiner PerkinsPerceptive AdvisorsBlue OwlRedmile GroupMichael J. Fox Foundation

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are Neuron23's investors?

Neuron23's investors include Kleiner Perkins, Perceptive Advisors, Blue Owl, Redmile Group, Michael J. Fox Foundation.

Where is Neuron23 headquartered?

Neuron23 is headquartered in San Francisco, United States.

What does Neuron23 do?

Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.

What stage is Neuron23 at?

Neuron23 is at the Grant stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 17, 2026.

MLA

"Neuron23 — Funding & Investors." VCBacked, June 17, 2026, https://www.vcbacked.co/company/neuron23. Accessed June 30, 2026.

APA

VCBacked. (2026). Neuron23 — Funding & Investors. Retrieved June 30, 2026, from https://www.vcbacked.co/company/neuron23

Wikipedia (cite web)

{{cite web |title=Neuron23 — Funding & Investors |url=https://www.vcbacked.co/company/neuron23 |website=VCBacked |access-date=June 30, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 17, 2026.